We are pleased to announce that Dr. David W. Eaker, Ph.D., DABT, recently joined ToxStrategies as a Senior Consultant in our Pharmaceutical practice. David has over 35 years of experience helping guide medical devices, drugs, and combination products from early concept through regulatory approval. His organic and analytical chemistry and toxicology background and training enables him to provide an integrative approach to preclinical program design that aligns toxicology, analytical data, preclinical functionality models, and clinical objectives. David supports clients at every stage of development, from experimental design and study data interpretation to regulatory submission and post-market strategy. This approach helps teams define gaps, manage risk, and ultimately present compelling, comprehensive program results.
David’s experience with medical device and drug delivery products includes surgical, interventional, and general device applications. He has supported hundreds of successful device and combination products 510(k), IDE and PMA submissions, EU MDR CE submissions, and China NMPA registrations. He has also collaborated on IND, NDA, and ANDA programs and materials regulation efforts (e.g., REACH; CA Prop 65, etc.).
To learn how David’s expertise can support your project needs, please reach out to David Eaker (deaker@toxstrategies.com) or Marcie Wood (mwood@toxstrategies.com). Or stop by our booth #1935 to chat with David and Marcie in person at the Society of Toxicology Annual Meeting in San Diego, March 22-25.
